• Established in 1993, Unimark Remedies Ltd. (“Unimark” or the “Company”) is engaged in the manufacturing and marketing of niche APIs, Intermediates and Injectables. • Its key products include Lisinopril, Imipenem, Nalidixic acid, Flecanide, Montelukast, Meropenem, etc. • The Company had market reach to supply its products to over 400 customers across 65 countries including major global pharma players. • It has strong product development and manufacturing capabilities and has successfully filed 52 DMFs (API & Intermediates). • It has also filed 15 ANDAs out of which 2 have already been approved and commercialized. Additional 9 are in various stages of development. • The Company has also filed dossiers for Carbapenem with US and EU regulatory authorities and is expecting approval.